Absci Corporation ABSI

Absci announced details for a planned global Phase 2 STORYLINE trial of ABS-201, an anti-prolactin receptor antibody designed with its generative AI platform, for endometriosis. The double-blind, randomized, placebo-controlled trial aims to evaluate efficacy and safety in participants with surgically diagnosed endometriosis and moderate-to-severe endometriosis-associated pain after a run-in period. Primary endpoints include reductions in dysmenorrhea and non-menstrual pelvic pain based on patient-reported measures. Approximately 150 patients from 10+ countries are expected to be enrolled, subject to protocol finalization and regulatory clearance. Absci plans to test two or three dose levels, with dose selection informed by data from the ongoing HEADLINE trial in pattern hair loss. Initiation of STORYLINE is anticipated in mid-2027. Absci emphasizes a non-hormonal approach and continued AI-driven drug design. Phase 2 initiation in mid-2027 with a two-to-three dose design for ABS-201 expands the program and could influence investor sentiment.

Absci's share price has surged, with the stock around $9.82, prompting questions whether the market value aligns with its book value. The company’s model requires heavy ongoing investment in R&D, facilities, and talent, which can distort balance-sheet assets and make book value a noisy measure for a loss-making biotech. Analysts show Absci trading around 6.8x P/B, well above biotech peers, implying a premium for expected pipeline progress, partnerships, and cash position. Bulls argue AI drug creation platforms ABS-101, ABS-301, and ABS-501 could unlock value, estimating about 29% undervaluation. Bears contend partnerships are not yet signed and the stock could be overvalued by around 116%. The piece notes Simply Wall St narratives and mentions forward analyst forecasts, but the path to fair value remains uncertain. Valuation-focused piece highlighting future pipeline milestones and partnerships as key drivers, which could influence sentiment but not reflect immediate fundamentals.

Absci Corporation held its Q2 2026 earnings call, covering quarterly financial results, operational updates and forward guidance. Earnings calls deliver financial results and guidance that move near-term valuation.

Absci releases early ABS 201 data and enters a Lilly deal that supports its valuation. Lilly deal and ABS 201 data mark strategic progress that can substantially lift Absci's trajectory and sentiment.

Eli Lilly invested US$40 million backing Absci's ABS-201 asset, lifting ABSI shares 11%. The move prompts reassessment of the company's bull case. Lilly's $40 million commitment supplies major external validation plus capital that can materially advance ABS-201 and reshape Absci's trajectory.

Absci Corporation targets its IPO as the biggest of the year within the next 60 days, potentially triggering a rally in an unexpected non-tech industry beforehand. Absci Corporation's largest IPO of the year will fundamentally redefine its access to capital and long-term market trajectory.

Absci Corporation presented Q2 2026 financial results and business updates during its earnings call. Quarterly earnings data supply performance metrics that can shift near-term investor views.

Absci Corporation reported Q2 results and strategic updates during its earnings call, including pipeline progress, partnerships, and financial position details. Q2 earnings call details provide updates on financials and pipeline that may influence near-term market sentiment but are not expected to fundamentally alter long-term trajectory.

Absci Corporation released business updates and second quarter 2026 financial and operating results. Quarterly results and updates supply financial metrics that can move near-term investor views on operations.

Absci presented at a major computing event on AI applications for drug discovery. Event presentation raises Absci visibility and signals AI-driven trajectory shift in drug discovery.

Absci Corporation raises $100 million in equity financing to fund AI-designed programs for hair loss and endometriosis. $100 million equity infusion supplies major capital to advance core AI drug programs and materially shifts company trajectory.

Absci Corporation raised $100 million backed by Lilly to advance endometriosis and hair loss therapies. The $100 million raise directly funds core pipeline advancement and strengthens financial runway for key programs.

Absci raises $100m backed by Lilly to advance endometriosis and hair loss treatments. Major funding round directly funds core pipeline programs and can materially lift valuation and execution runway.

Absci (ABSI) shares rose 37.8% after ABS-201 data release and equity raise. ABS-201 data and equity raise alter Absci development pipeline and cash position.

Absci Corporation (ABSI) shares rose 36% after positive interim data from a Phase I hair loss study. Positive Phase I hair loss study results triggered a 36% stock surge indicating significant future market performance potential.

Absci Corporation eyes its best trading day after positive hair loss drug data and a $100 million Lilly-backed raise. Positive hair loss drug data plus $100 million Lilly-backed funding signals major strategic progress and funding that can sharply lift Absci's trajectory.

Absci shares surge on positive early clinical results for hair loss therapy. Positive early clinical results for hair loss therapy signal major potential revenue growth and market revaluation for Absci.

Absci announces positive interim Phase 1 data from the HEADLINE trial of ABS-201, a novel antibody targeting the prolactin receptor. Positive Phase 1 data for ABS-201 advances Absci's clinical pipeline and may drive valuation gains.

Absci Corporation prices $100 million underwritten offering with leading strategic and financial investors. $100 million capital raise bolsters balance sheet and extends runway while diluting shareholders.

Guggenheim expresses bullish outlook on Absci Corporation (ABSI). Analyst bullishness from Guggenheim can moderately sway short-term investor sentiment and trading activity for ABSI.

Absci Corporation (ABSI) is identified as the top AI stock recommended for long-term holding through 2036. Long-term bullish endorsement may moderately lift investor sentiment toward Absci's AI platform.

Absci (ABSI) Q1 2026 earnings call transcript released, covering first-quarter financial results, operational updates, and forward-looking guidance. Q1 2026 earnings call transcript reveals financial metrics, pipeline progress, and strategic initiatives directly influencing Absci's market performance and investor outlook.

Absci Corporation (ABSI) reported a Q1 loss and missed revenue estimates. Q1 loss and revenue shortfall directly hit financial performance, influencing investor sentiment and short-term market trajectory.

Absci Corporation's Q1 earnings call highlighted financial results with $1.2 million revenue, $62.4 million cash position, narrowed net loss to $26 million, pipeline advancements including ABS-101 IND filing planned for 2025, and new partnerships. Q1 earnings show financial stability and pipeline progress but limited revenue and ongoing losses temper broader trajectory shifts.

Absci Corporation released business updates and first quarter 2026 financial and operating results. Quarterly financial results and business updates directly impact financial performance and investor sentiment.

Absci showcased its AI-powered antibody platform at the Needham Healthcare Conference, teased upcoming ABS-201 data for hair-loss treatment, and outlined 2026 milestones including IND filings and clinical readouts. Teasing ABS-201 hair-loss data and 2026 milestones highlights pipeline progress in a lucrative market, likely driving significant investor sentiment and stock movement.

Absci Corporation (ABSI) draws investor scrutiny over its rapid cash burn, raising concerns about financial runway and future funding needs. Absci's cash burn situation highlights financial pressures that could moderately affect performance and investor sentiment.

Absci (ABSI) Q4 2025 earnings call transcript released, covering financial results, operational updates, and forward-looking guidance. Q4 earnings results, pipeline progress, and guidance in Absci's call represent major strategic disclosures likely to shift investor sentiment and stock performance.

Absci Corporation (ABSI) released Q4 2025 earnings call summary detailing financial results, pipeline updates, and future guidance. Q4 earnings summaries disclose key financial metrics, clinical progress, and strategic outlook that drive significant investor reactions and stock volatility.

Absci Corp (ABSI) Q4 2025 earnings call highlights strategic advances including pipeline progress, partnerships, and AI platform enhancements alongside financial resilience with improved cash position and reduced burn rate. Strategic advances in AI-driven drug discovery and financial resilience position Absci for significant trajectory shifts and positive investor sentiment.